Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
2002 1
2003 1
2004 4
2005 3
2007 3
2008 2
2009 6
2010 5
2011 4
2012 2
2013 5
2014 15
2015 11
2016 14
2017 24
2018 20
2019 24
2020 25
2021 49
2022 41
2023 45
2024 15

Text availability

Article attribute

Article type

Publication date

Search Results

286 results

Results by year

Filters applied: . Clear all
Page 1
Change in albuminuria and subsequent risk of end-stage kidney disease: an individual participant-level consortium meta-analysis of observational studies.
Coresh J, Heerspink HJL, Sang Y, Matsushita K, Arnlov J, Astor BC, Black C, Brunskill NJ, Carrero JJ, Feldman HI, Fox CS, Inker LA, Ishani A, Ito S, Jassal S, Konta T, Polkinghorne K, Romundstad S, Solbu MD, Stempniewicz N, Stengel B, Tonelli M, Umesawa M, Waikar SS, Wen CP, Wetzels JFM, Woodward M, Grams ME, Kovesdy CP, Levey AS, Gansevoort RT; Chronic Kidney Disease Prognosis Consortium and Chronic Kidney Disease Epidemiology Collaboration. Coresh J, et al. Lancet Diabetes Endocrinol. 2019 Feb;7(2):115-127. doi: 10.1016/S2213-8587(18)30313-9. Epub 2019 Jan 8. Lancet Diabetes Endocrinol. 2019. PMID: 30635225 Free PMC article.
We quantified associations of percentage change in albuminuria with subsequent end-stage kidney disease using Cox regression in each cohort, followed by random-effects meta-analysis. ...
We quantified associations of percentage change in albuminuria with subsequent end-stage kidney disease using Cox regression in each …
Methods to Analyze Time-to-Event Data: The Cox Regression Analysis.
Abd ElHafeez S, D'Arrigo G, Leonardis D, Fusaro M, Tripepi G, Roumeliotis S. Abd ElHafeez S, et al. Oxid Med Cell Longev. 2021 Nov 30;2021:1302811. doi: 10.1155/2021/1302811. eCollection 2021. Oxid Med Cell Longev. 2021. PMID: 34887996 Free PMC article.
The Cox model is a regression technique for performing survival analyses in epidemiological and clinical research. ...A fundamental assumption underlying the application of the Cox model is proportional hazards; in other words, the effects of different variables on …
The Cox model is a regression technique for performing survival analyses in epidemiological and clinical research. ...A fundamental a …
Rational design of biodegradable sulphonamide candidates treating septicaemia by synergistic dual inhibition of COX-2/PGE2 axis and DHPS enzyme.
El-Dershaby NH, El-Hawash SA, Kassab SE, Dabees HG, Abdel Moneim AE, Abdel Wahab IA, Abd-Alhaseeb MM, El-Miligy MMM. El-Dershaby NH, et al. J Enzyme Inhib Med Chem. 2022 Dec;37(1):1737-1751. doi: 10.1080/14756366.2022.2086868. J Enzyme Inhib Med Chem. 2022. PMID: 35707920 Free PMC article.
A new series of co-drugs was designed based on hybridising the dihydropteroate synthase (DHPS) inhibitor sulphonamide scaffold with the COX-2 inhibitor salicylamide pharmacophore through biodegradable linkage to achieve compounds with synergistic dual inhibition of COX …
A new series of co-drugs was designed based on hybridising the dihydropteroate synthase (DHPS) inhibitor sulphonamide scaffold with the C …
Novel 1,5-diaryl pyrazole-3-carboxamides as selective COX-2/sEH inhibitors with analgesic, anti-inflammatory, and lower cardiotoxicity effects.
Hendawy OM, Gomaa HAM, Alzarea SI, Alshammari MS, Mohamed FAM, Mostafa YA, Abdelazeem AH, Abdelrahman MH, Trembleau L, Youssif BGM. Hendawy OM, et al. Bioorg Chem. 2021 Nov;116:105302. doi: 10.1016/j.bioorg.2021.105302. Epub 2021 Aug 24. Bioorg Chem. 2021. PMID: 34464816
COX-2 selective drugs have been withdrawn from the market due to cardiovascular side effects, just a few years after their discovery. ...The target compounds were synthesized and tested in vitro against COX-1, COX-2, and sEH enzymes. Compounds 20, 22 and 29 e …
COX-2 selective drugs have been withdrawn from the market due to cardiovascular side effects, just a few years after their discovery. …
Celecoxib repurposing in cancer therapy: molecular mechanisms and nanomedicine-based delivery technologies.
Khafaga AF, Shamma RN, Abdeen A, Barakat AM, Noreldin AE, Elzoghby AO, Sallam MA. Khafaga AF, et al. Nanomedicine (Lond). 2021 Aug;16(19):1691-1712. doi: 10.2217/nnm-2021-0086. Epub 2021 Jul 15. Nanomedicine (Lond). 2021. PMID: 34264123 Review.
Drug repurposing poses several advantages as reduced cost and better safety compared with new compounds development. COX-2 inhibitors are one of the most promising drug classes for repurposing in cancer therapy. In this review, we provide an overview of the detailed mechan …
Drug repurposing poses several advantages as reduced cost and better safety compared with new compounds development. COX-2 inhibitors …
Human genome meeting 2016 : Houston, TX, USA. 28 February - 2 March 2016.
Srivastava AK, Wang Y, Huang R, Skinner C, Thompson T, Pollard L, Wood T, Luo F, Stevenson R, Polimanti R, Gelernter J, Lin X, Lim IY, Wu Y, Teh AL, Chen L, Aris IM, Soh SE, Tint MT, MacIsaac JL, Yap F, Kwek K, Saw SM, Kobor MS, Meaney MJ, Godfrey KM, Chong YS, Holbrook JD, Lee YS, Gluckman PD, Karnani N; GUSTO study group; Kapoor A, Lee D, Chakravarti A, Maercker C, Graf F, Boutros M, Stamoulis G, Santoni F, Makrythanasis P, Letourneau A, Guipponi M, Panousis N, Garieri M, Ribaux P, Falconnet E, Borel C, Antonarakis SE, Kumar S, Curran J, Blangero J, Chatterjee S, Kapoor A, Akiyama J, Auer D, Berrios C, Pennacchio L, Chakravarti A, Donti TR, Cappuccio G, Miller M, Atwal P, Kennedy A, Cardon A, Bacino C, Emrick L, Hertecant J, Baumer F, Porter B, Bainbridge M, Bonnen P, Graham B, Sutton R, Sun Q, Elsea S, Hu Z, Wang P, Zhu Y, Zhao J, Xiong M, Bennett DA, Hidalgo-Miranda A, Romero-Cordoba S, Rodriguez-Cuevas S, Rebollar-Vega R, Tagliabue E, Iorio M, D’Ippolito E, Baroni S, Kaczkowski B, Tanaka Y, Kawaji H, Sandelin A, Andersson R, Itoh M, Lassmann T; The FANTOM5 Consortium; Hayashizaki Y, Carninci P, Forrest ARR, Semple CA, Rosenthal EA, Shirts B, Amendola L, Gallego C, Horike-Pyne… See abstract for full author list ➔ Srivastava AK, et al. Hum Genomics. 2016 May 26;10 Suppl 1(Suppl 1):12. doi: 10.1186/s40246-016-0063-5. Hum Genomics. 2016. PMID: 27294413 Free PMC article.
Gibbs O58 Rhesus macaques exhibit more non-synonymous variation but greater impact of purifying selection than humans R. A. Harris, M. Raveenedran, C. Xue, M. Dahdouli, L. Cox, G. Fan, B. Ferguson, J. Hovarth, Z. Johnson, S. Kanthaswamy, M. ...
Gibbs O58 Rhesus macaques exhibit more non-synonymous variation but greater impact of purifying selection than humans R. A. Harris, M. Ravee …
Rational Design and Synthesis of New Selective COX-2 Inhibitors with In Vivo PGE2-Lowering Activity by Tethering Benzenesulfonamide and 1,2,3-Triazole Pharmacophores to Some NSAIDs.
El-Dershaby NH, El-Hawash SA, Kassab SE, Daabees HG, Abdel Moneim AE, El-Miligy MMM. El-Dershaby NH, et al. Pharmaceuticals (Basel). 2022 Sep 20;15(10):1165. doi: 10.3390/ph15101165. Pharmaceuticals (Basel). 2022. PMID: 36297278 Free PMC article.
New selective COX-2 inhibitors were designed and synthesized by tethering 1,2,3-triazole and benzenesulfonamide pharmacophores to some NSAIDs. ...In conclusion, compounds 6b and 6j better achieved the target goal as more potent and selective COX-2 inhibitors than ce …
New selective COX-2 inhibitors were designed and synthesized by tethering 1,2,3-triazole and benzenesulfonamide pharmacophores to som …
286 results